PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
38.10%
Revenue growth at 50-75% of 4997.T's 58.32%. Martin Whitman would worry about competitiveness or product relevance.
-1.49%
Negative gross profit growth while 4997.T is at 50.43%. Joel Greenblatt would examine cost competitiveness or demand decline.
-38.17%
Negative EBIT growth while 4997.T is at 110.95%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-24.64%
Negative operating income growth while 4997.T is at 110.95%. Joel Greenblatt would press for urgent turnaround measures.
-27.98%
Negative net income growth while 4997.T stands at 101.83%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-28.02%
Negative EPS growth while 4997.T is at 92.08%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-28.02%
Negative diluted EPS growth while 4997.T is at 92.08%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.38%
OCF growth of 14.38% while 4997.T is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
14.38%
FCF growth of 14.38% while 4997.T is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
67.46%
10Y revenue/share CAGR 1.25-1.5x 4997.T's 46.07%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
-49.63%
Negative 5Y CAGR while 4997.T stands at 15.13%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-22.53%
Negative 3Y CAGR while 4997.T stands at 20.27%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.05%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-84.89%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-74.03%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
107.45%
10Y equity/share CAGR above 1.5x 4997.T's 59.50%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
29.24%
5Y equity/share CAGR above 1.5x 4997.T's 12.18%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
21.55%
3Y equity/share CAGR 1.25-1.5x 4997.T's 15.49%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.74%
Firm’s AR is declining while 4997.T shows 47.46%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-21.30%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-7.12%
Negative asset growth while 4997.T invests at 10.82%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.72%
Under 50% of 4997.T's 4.28%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-11.27%
We’re deleveraging while 4997.T stands at 34.63%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-11.76%
Our R&D shrinks while 4997.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
9.10%
SG&A growth of 9.10% while 4997.T is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.